An Open Label, Single Treatment, Single Arm, Multiple Dose Phase-2 Study to Evaluate the Pharmacokinetics, Safety, and Clinical Performance of EscharEx (EX-03) in Participants With Venous Leg Ulcers
← catalyst calendarNCT07692178 · readout ≤ 743 d
Sponsored by MediWound Ltd (industry) · MDWD — their whole pipeline →. With TFS HealthScience.
Phase
Phase 2
Status
Not yet recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
20estimated
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | Aug 2026 | estimated | When the study began enrolling |
| Primary completion | Aug 2028 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Aug 2028 | estimated | The whole study's end, after follow-up |
| First posted | 2026-07-09 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-09 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Venous Leg Ulcer (VLU)
Intervention
- Drug: EX-03 — also filed as Gel vehicle, 5% EscharEx, EX-03 formulation
Primary outcomes
what the primary-completion date above is the date OFPK Evaluation
measured Up to 2 weeks
Safety and Tolerability Endpoints
measured up to 5 weeks
PK Evaluation
measured Up to 2 weeks
Permalink · MDWD's whole pipeline · Catalyst calendar · Every registered study · What changed